Author Archives: lhg-dev

Irvine, Calif., Oct. 28, 2020 (Company release) — PeproMene Bio Inc. announced today it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to study a novel chimeric antigen receptor (CAR) T cell … Continue reading →

Irvine, CA, September 26, 2019 – Yesterday, an article, “CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies”, has been published at Science Translational Medicine. To find the article on the web: https://stm.sciencemag.org/content/11/511/eaaw9414 About PeproMene Bio … Continue reading →

Irvine, CA, June 22, 2018 – PeproMene Bio, Inc., a development stage biotechnology company focused on BAFF-R target CAR-T cell to develop novel cancer and immuno-oncology therapies, today announced the appointment of Steven T. Rosen as its Scientific Advisor. Bryan … Continue reading →

Irvine, CA, December 11, 2017 – Today, PeproMene Bio, Inc. announced that Dr. Hong Qin, a member of its Scientific Advisory Board, posted a paper at 59th ASH annual meeting in regards to “CAR-T Cells Targeting BAFF-Receptor for B-Cell Malignancies: … Continue reading →